SEARCH

SEARCH BY CITATION

References

  • 1
    Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza-Mataftsi E. Influenza A (H5N1): an overview of the current situation. Eurosurveillance 2009; 145:220226.
  • 2
    World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 6 May 2010. Global alert and response (GAR). Available at http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_03_07/en/index.html (Accessed 26 July 2011).
  • 3
    World Health Organization (WHO). Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for the development of candidate vaccine viruses for pandemic preparedness, February 2011. Available at http://www.who.int/csr/disease/avian_influenza/guidelines/2011_02_h5_h9_vaccinevirusupdate.pdf (Accessed 23 May 2011).
  • 4
    Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on Avian Influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261273.
  • 5
    European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
  • 6
    US Food and Drug Administration (FDA) Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007. Available at http://www.fda.gov/cber/gdlns/panfluvac.htm (Accessed 10 March 2011).
  • 7
    World Health Organization (WHO). Options for the Use of Human H5N1 Influenza Vaccines and the WHO H5N1 Vaccine Stockpile. Geneva, Switzerland: WHO scientific consultation, 2007.
  • 8
    Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458460.
  • 9
    World Health Organization. Pandemic (H1N1) 2009 briefing note 2. Global alert and response (GAR). July 13, 2009. Available at http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html (Accessed 16 March 2011).
  • 10
    Chu DW-S, Hwang SJ, Lim FS et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009; 27:74287435.
  • 11
    Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580589.
  • 12
    Leroux-Roels I, Bernhard R, Gerard P, Dramé M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008; 3:e1665. 499. Doi: 10.1371/journal.pone.0001665.
  • 13
    Rümke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:23782388.
  • 14
    Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:62846290.
  • 15
    Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:9195.
  • 16
    Reed LT, Muench H. A simple method of calculating fifty percent end point. Am J Hyg 1938; 27:493498.
  • 17
    Moris P, van der Most R, Leroux-roels I et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443454.
  • 18
    Malherbe L, Mark L, Fazilleau N, Heyzer-Williams LJ, Heyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008; 28:698709.
  • 19
    Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48.